The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback